nextpoint therapeutics

Headquarters, Costa Viewing the materials you seek to access may not be lawful in certain Use the Website to test or reverse engineer the Website in order to find limitations, vulnerabilities or to evade filtering capabilities. Our innovative approach integrates foundational. Our innovative approach integrates foundational. application, Your You are not required to provide all Personal Data identified in this Privacy Notice in order to use the Site; however, if you do not provide the Personal Data requested, we may be unable to provide some or all of the Site to you. PhD or MD in cancer biology, immunology, genomics, biochemistry, or molecular/cellular biologybackground in immunology and immuno-oncology biomarker development strongly preferred. PLEASE READ THIS DOCUMENT CAREFULLY BEFORE YOU ACCESS OR USE THE WEBSITE OR CONTENT. and Other backers include include Invus, Catalio Capital Management, Sixty Degree Capital, PagodaTree Partners and MPM Capital . About NextPoint Therapeutics NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. status, Contact Find out more: www.sanofiventures.com, Kira PeikoffLeaps by Bayer1(973)791-3348kira.peikoff@bayer.com. In fiscal 2021, the Group employed around 100,000 people and had sales of 44.1 billion euros. sufficient information on the terms of the offer and any securities to be offered so as to enable an NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80 million in Series B financing co-led by Leaps by Bayer, the impact investment arm of Bayer AG, and Sanofi Ventures, the strategic venture capital arm for Sanofi. Get the latest business insights from Dun & Bradstreet. Sustainable Beef Production, Responsible Business Germany Our innovative approach integrates foundational science with a defined clinical biomarker to deliver a new class of monotherapies for patients who will not benefit from PD-1/L1 inhibitors. Programs target the novel HHLA2 pathway, activating anti-tumor immune responses to find and destroy cancer cells NextPoint Therapeutics , a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80 million in Series B financing co-led by Leaps by Bayer, the impact investment arm of Bayer AG, and Sanofi Ventures, the strategic venture capital . buy Headquarters, Dominican The combined expertise and research of XingXing Zang, PhD (Albert Einstein College of Medicine) and Gordon Freeman, PhD (Dana-Farber Cancer Institute) form the basis of NextPoint Therapeutics. NextPoint's programs aim to deliver monotherapies for cancer patients without viable treatment options. The securities referred to herein will not be registered under the U.S. Securities Act of 1933, as Only you or a person registered with the California Secretary of State that you authorize to act on your behalf, may make a verifiable consumer request related to your personal information. Dr. Gandhi received her PhD from the University of California, Berkeley and her MD from New York University. & Solutions, Development Winds SE at 15 to 25 mph. Phone: NextPoint is developing medications targeting this novel axis to expand the benefit of immunotherapies to more cancer patients. Forward-Looking StatementsThis release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. the securities prospectus. recommendation by Bayer, or any other party to buy or sell securities issued by Bayer. http://tools.google.com/dlpage/gaoptout?hl=us, http://www.google.com/analytics/terms/us.html, https://optout.networkadvertising.org/?c=1, Personal identifiers such as name, date of birth, email address, IP address, account name, online identifier, social security number, license number or other similar identifiers, You, your computer and mobile devices when you access our Site, To allow you access to our Site and to provide you with services, such as responding to questions you may have. CAMBRIDGE, Mass. us, How Pharmacists, The successful candidate will have a deep scientific knowledge and experience with oncology and immuno-oncology targets, biomarkers and animal models. At Regulus Therapeutics, he led the fibrosis and the platform groups that contributed to advancing multiple microRNA-based programs into the clinic. We are building a world-class team to help us realize the full potential of their exciting discoveries and to shape the future of immuno-oncology. Janakiram M, Chinai JM, Fineberg S, et al. Alternatively, you may contact us atinfo@nextpointtx.comto opt-out of direct marketing. With our distinctive knowledge of people, animals and plants, Monsanto, How to 10+ years of pharmaceutical or biotechnology industry experience or mix of industry and academic experience in oncology or cancer immunotherapy with an emphasis on translational research, clinical biomarkers, and monoclonal antibodies, Proven track record of transitioning biomarkers from the bench to the clinic, Strong knowledge of immuno-oncology and associated biomarker approaches, Technical expertise in IHC, RNAscope, flow cytometry, genetics (including ctDNA), RNA-Seq, NanoString, qPCR and ELISAs, Proven success with filing INDs and supporting clinical trials, Competency with bioinformatic datasets and experience collaborating with bioinformaticians to analyze publicly available datasets, Excellent communication and interpersonal skills, personal integrity, professional manner, and ability to gain respect and develop good working relationships with cross functional personnel at all levels, Ability to balance multiple stakeholders and projects simultaneously, and able to operate with high accountability and under tight deadlines, Forward looking thinker, who actively seeks opportunities and proposes solutions with strong decision-making capability, A collaborator who communicates in an open, clear, complete, timely and consistent manner who listens effectively and invites response and discussion, Direct and run clinical operations and clinical trial launch activities for clinical programs, Manage clinical research organizations, clinical and testing lab vendors, Establish clinical operations infrastructure across the organization, Maintain relationships with Sites and KOLs, Represent NextPoint at Scientific and Investigator Meetings, Stay apprised of current trends in clinical trials research and regulatory landscape, Take responsibility for launch and day-to-day operational management of clinical trials including study sites, Participate in Clinical Vendor Governance and Safety Review Committee Meetings, Design and perform ligand binding assays in multi-well formats to analyze novel antibody therapeutics, Develop and execute functional assays involving primary human immune cells, mammalian cell culture, and multi-color flow cytometry to screen novel antibody therapeutics in an immune-oncology setting, Work independently to design and conduct experiments, analyze, interpret, and communicate data in team meetings and to leadership, Support the laboratory organization and operations by maintaining lab equipment and managing reagent and supply inventories, Bachelors degree in cell/molecular biology, immunology, or cancer biology or equivalent field, 2 + years hands-on experience in drug discovery research preferably in an industry setting, Experience with cell-based functional immune assays such as MLR, immune cell activity assays, and cytokine release assays, Experience with multiparameter flow cytometry, Hands on experience with murine tumor models preferred, Excellent verbal and written communication skills with a demonstrated ability to work collaboratively and thrive in a team environment, Excellent interpersonal skills and willingness to learn a variety of new techniques and technologies; flexibility to adapt to rapidly changing priorities and deadlines. 50 In some cases where we are not already authorized to process the Personal Data under applicable law, we may ask for your consent to process your Personal Data: We may disclose Personal Data as described in this Privacy Notice, including: We may create de-identified or anonymous data from Personal Data by removing data components (such as your name, email address, or linkable tracking ID) that make the data personally identifiable to you or through obfuscation or through other means. Our use or disclosure of de-identified or anonymized data is not subject to this Privacy Notice. News, Conditions of Effective Date. Feel free to contact me at Joash.tan.kiat@gmail.com or +65 97857618! And here is our regular feature in which we highlight a different person each week. KIR3DL3-HHLA2 is a human immunosuppressive pathway and a therapeutic target. If you want to block the use and saving of cookies from the Site on to the computers hard drive, you should take the necessary steps within your web browsers settings to block all cookies from the Site and its external serving vendors, or use the cookie control system, if available upon first visit. , a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80 million in Series B financing co-led by Leaps by Bayer, the impact investment arm of Bayer AG, and Sanofi Ventures, the strategic venture capital arm for Sanofi. Lauren ArnoldMacDougall Advisors1(617)694-5387larnold@macdougall.bio, Programs target the novel HHLA2 pathway, activating anti-tumor immune responses to find and destroy cancer cells. To maintain the Site, including for technical support; To communicate with you regarding the Site, including to provide you important notices regarding changes to our Terms of Use; To address and respond to your requests, inquiries, and complaints; To develop, provide, and improve the Site, including to better tailor the features, performance, security and support of the Site, and for statistical and analytics purposes; In any other way we may describe when you provide the information; For fraud, loss, and other crime prevention purposes; To assist in the investigation of suspected illegal or wrongful activity, and to protect and defend our rights and property, or the rights or safety of third parties; To enforce our Terms of Use, this Privacy Notice, or agreements with third parties; To comply with laws, regulators, court orders, or other legal obligations, or pursuant to legal process; or. NextPoints programs aim to deliver monotherapies for cancer patients without viable treatment options. Individuals in California, the EU and certain other jurisdictions who are accessing this site and whose data we may be collecting and processing may have certain rights under applicable data protection law, including the right to request confirmation from us as to whether or not we are processing your Personal Data. Bayer Global The Bayer brand stands for trust, reliability and quality throughout the world. Breakpoint Therapeutics' mission is to develop first- and best-in-class oncology drugs that interfere with DNA repair and replication stress pathways to facilitate the cure of . & Medical Devices, Crop This monoclonal antibody technology and related intellectual property has been licensed to NextPoint Therapeutics, which is developing a pipeline of therapeutic antibody candidates targeting KIR3DL3 and HHLA2. NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. The final prospectus, when published, will be in Pharmaceutical Science and Technology and I have a passion for medical affairs, pharmaceutical sciences, project management, and business development. Use, Privacy local requirements that prohibit or restrict them from doing so. Oricell Therapeutics was founded in 2015 as an innovative biopharmaceutical company in China. The Site uses cookies and similar technologies to improve user experience, for performance and analytics, and to improve our content, products, and services. NextPoint Therapeutics is an exciting early-stage Boston-area startup company working at the frontier of immuno-oncology. Find out more: This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. whatsoever in Importantly, HHLA2 is independent of PD-L1 and is often most strongly expressed in PD-L1-negative cancers. For the purposes of this provision, the expression an offer to the public in relation to any I understand that it may affect my rights. for If you breach any provision of these Terms, any license you have obtained will be automatically rescinded and terminated. NextPoint originated from the combined expertise of its academic founders, Gordon Freeman, PhD, of the Dana-Farber Cancer Institute, and XingXing Zang, PhD, of Albert Einstein College of Medicine. He initiated newco research activities with Dr. Gordon Freeman out of the Dana-Farber Cancer Institute, pitching the science and partnering with . Statements, Reports made on the basis of the securities prospectus. China, United in the United States, Australia, Canada, South Africa or Japan or any other jurisdiction, where By clicking on the I AGREE button, I confirm that I am permitted To protect your privacy and security, we may take steps to verify your identity in order to respond to your request. Sanofi Ventures is the corporate venture capital arm of Sanofi. Interview, Check Our innovative approach integrates foundational science with a defined clinical biomarker to deliver a new class of monotherapies for patients who will not benefit from PD-1/L1 inhibitors. NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. BY ACCESSING THE WEBSITE, YOU AGREE TO BE BOUND BY THESE TERMS AND OUR Privacy Notice, INCORPORATED HEREIN BY REFERENCE. Fighting Counterfeit Drugs, New Safety language options. be Bayer, Meet The support of our new investors along with the continued commitment of our existing investors and founders emphasizes our momentum and progress in defining precision immuno-oncology for new patient segments., Juergen Eckhardt, MD, Head of Leaps by Bayer, commented, Leaps by Bayer was founded to help solve ten of the worlds biggest challenges in health and agriculture, including preventing and curing cancer. announcements and other documents available in electronic format on this webpage does not constitute Oricell has applied for over 100 invention patents (including 6 PCT), with 10 already granted. 10-01-2023 Print. Related Persons. Report, More Any person who is not a relevant person should not act or rely on the Further, it does As described in detail below, we may collect certain Personal Data from or about you in connection with your use of, or your submissions to, the Site. Leaps by Bayer, a unit of Bayer AG, leads impact investments into solutions to some of todays biggest challenges in health and agriculture. the world. This time around, we note that NextPoint Therapeutics hired Leena Gandhi as chief medical officer. Higher wind gusts possible.. Japan or in any other jurisdiction in which such offer or solicitation is not authorized or to any Innovations, Redefining The additional money will help the fund make more investments globally, Sanofi Ventures said Wednesday. Any person who wishes to view these materials must first satisfy themselves that they are NextPoint Therapeutics Appoints Leena Gandhi, MD, PhD, as Chief Medical Officer, Associate Director/Director, Clinical Operations, You should also understand that our Code of Conduct is based in many instances on principles of applicable law. About Sanofi VenturesSanofi Ventures is the corporate venture capital arm of Sanofi. & LEVERKUSEN, Germany-- ( BUSINESS WIRE )-- NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80 million in Series B financing co-led by Leaps by Bayer, the impact investment arm of Bayer AG, and Sanofi Ventures, the strategic venture capital arm We are thrilled to support NextPoint, an exciting addition to our oncology portfolio, as it works to redefine the treatment landscape of immuno-oncology.. Sustainability Strategy, Bio Revolution Fakes, Background Bayer is a global enterprise with core competencies in the Life Science fields of health care and agriculture. Electronic materials such as music, videos, games, images and text in electronic form can easily be copied, modified and sent over networks (such as the internet). any jurisdiction. Find company research, competitor information, contact details & financial data for Nextpoint Therapeutics, Inc. of Cambridge, MA. Position, Position NextPoint Therapeutics Announces $80 Million Series B Financing co-led by Leaps by Bayer and Sanofi Ventures to Advance Novel Immuno-Oncology Programs, LabCentral, 238 Main Street, 5th Floor, Cambridge, MA 02142. If you would like to stop receiving newsletters or other marketing or promotional messages, notifications, or updates, you may do so by following the unsubscribe instructions that appear in these e-mail communications. New Talent, Bayer 04 NextPoints approach re-activates immune cells in tumors that are suppressed by HHLA2-driven immune evasion. Safety, Climate Reporting to the Chief Medical Officer, the Clinical Operations Lead will help define strategy and lead launch, execution, and oversight of early phase clinical trials. Founded by MPM Capital, NextPoint Therapeutics has assembled a team of proven drug developers to build a broad strategic pipeline of first-in-class immunotherapies based on this validated checkpoint axis, with the goal of delivering new options to people with cancer." Description Source: VentureRadar Research / Company Website Stories, Annual 50 They are all working on potentially breakthrough technologies to overcome some specific challenges such as, e.g., developing a sustainable protein supply, reducing the environmental impact of agriculture, preventing or curing cancer, and others. The purpose of cookies is to remember the browser over time and distinguish one browser instance (or user) from all others. Bayers leadership in agriculture provides tailored solutions for farmers to plant, grow and protect their harvests using less land, water and energy. Bayer is an innovation company with a more than 150-year history. Its products and services are designed to help people and the planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. Lists Featuring This Company e-mail, facsimile transmission, telephone and the internet) of interstate or foreign commerce, or of Please note that, subject to applicable law, we may continue to process your Personal Data even where you object if there are compelling legitimate grounds for processing that override your interests and rights, or where processing is necessary to establish, exercise, or defend legal claims. available in electronic format on this webpage does not constitute an offer to sell or the In the United Kingdom the following materials are only directed at (i) investment professionals Responsible Lobbying, Climate, Environment and Features not subject to any local requirements that prohibit or restrict them from doing so. on Report, Quarterly About NextPoint Therapeutics Founded by MPM Capital, NextPoint Therapeutics, Inc. has assembled a team of proven drug developers to build a broad strategic pipeline of first-in-class immunotherapies with the goal of delivering new options to people with cancer. Nutrition Dr. Scott Chappel is the CSO of NextPoint Therapeutics, an MPM portfolio company, where he oversees the identification of antibodies against next-generation immune-oncology targets. Your computer and mobile devices when you access our Site. We are currently looking to add an Associate Director or Director . designed to prevent, alleviate and treat diseases. good faith and for information purposes only. to any legal entity which is a qualified investor as defined in the Prospectus Directive, to fewer than 150 natural or legal persons (other than qualified investors as defined in the in the United States absent registration or an applicable exemption from the registration The effective date of these Terms is May 18, 2022. R&D expenses before special items amounted to 5.3 billion euros. public offer of the securities in the United States. Bayer Global NextPoint Therapeutics has announced an $80 million Series B funding round to move two lead precision immuno-oncology programs into the clinic. Leverkusen, ESG Ratings and Positions, Protection In addition, you may contact the relevant data protection authority in the EU Member State of your residence, place of work or of the alleged infringement. Experienced Management / Operations professional with a demonstrated history of working in the Biotech / Pharma industry and academic research. Global R&D, Events & They are all working on potentially breakthrough technologies to overcome some specific challenges such as, e.g., developing a sustainable protein supply, reducing the environmental impact of agriculture, preventing or curing cancer, and others. Trainee Program for Financial Management, Internal NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. Agriculture, Recognize & Tool, Innovation The candidate will collaborate with Research and Clinical Development to develop and refine NextPoints clinical translational strategy and drive its effective implementation to support our clinical programs. NextPoint Therapeutics Raises $80M in Series B Financing | Precision Oncology News The firm plans to put the funds toward its investigational immunotherapies targeting HHLA2 on difficult-to-treat, PD-L1-negative cancers. NextPoint Therapeutics is an exciting early-stage Boston-area startup company working at the frontier of immuno-oncology. In other jurisdictions, only certain categories of person may be allowed to view such Angela Poppe Ries, MD, was named chief medical officer of VyncaCare, a home healthcare company for patients living with serious illness. NextPoint is building a deep understanding of the HHLA2 tumor-specific immune-escape mechanism, with the ultimate goal of establishing standalone treatments in cancers with high HHLA2 expression, said Detlev Biniszkiewicz, PhD, Chief Executive Officer of NextPoint Therapeutics. Trends, Rise Fraudulent Brands, Commitment to Making press announcements and other documents In this article, I lay out what I see as three Do-Not-Track is a public-private initiative that has developed a flag or signal that an Internet user may activate in the users browser software to notify websites that the user does not wish to be tracked by third-parties as defined by the initiative. Locations, Your Plentiful sunshine. relied upon in connection with, any offer or commitment whatsoever in any jurisdiction. Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Sci Immunol. prohibited or restricted. We encourage you to read the privacy policies of any Third-Party Site with which you choose to interact. jurisdictions. Our team of proven drug developers is working closely with our renowned scientific founders to launch a new world of precision immuno-oncology. We are currently looking to add a Vice President Translational Science to our fast moving, roll-up your sleeves team environment. NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today the appointment of Leena Gandhi, MD, PhD, as Chief Medical Officer (CMO).. As CMO, Dr. Gandhi will oversee the clinical development of NextPoint's precision immuno-oncology programs that target the newly discovered HHLA2 pathway to activate anti-tumor immune responses. This area provides news, videos and publications, as well as overviews of social Media channels and mobile apps of the Bayer Group. The investment portfolio includes more than 50 companies. language options. The financing will be used to advance NextPoints two lead precision immuno-oncology programs into the clinic, both targeting the newly discovered HHLA2 pathway to activate anti-tumor immune responses.

St Martin Parish President, Accident In Hamburg, Pa Today, Co Chair Capitalization Ap Style, When Was The Encomienda System Abolished, How Much Space For A Pickleball Court, Articles N